ES2191960T3 - Composiciones farmaceuticas que contienen un par acido-base efervescente. - Google Patents

Composiciones farmaceuticas que contienen un par acido-base efervescente.

Info

Publication number
ES2191960T3
ES2191960T3 ES98941377T ES98941377T ES2191960T3 ES 2191960 T3 ES2191960 T3 ES 2191960T3 ES 98941377 T ES98941377 T ES 98941377T ES 98941377 T ES98941377 T ES 98941377T ES 2191960 T3 ES2191960 T3 ES 2191960T3
Authority
ES
Spain
Prior art keywords
acid
efervescent
tablets
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98941377T
Other languages
English (en)
Inventor
Paolo Chiesi
Paolo Ventura
Rosa Mezzadri
Gaetano Brambilla
Daniela Acerbi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Application granted granted Critical
Publication of ES2191960T3 publication Critical patent/ES2191960T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica que se presenta en forma de comprimidos efervescentes que comprende un principio activo y una mezcla efervescente, comprendiendo esta mezcla efervescente un componente ácido y carbonato de glicina sódica como componentes alcalinos. El constituyente ácido preferido puede ser ácido fumárico, ácido maleico así como sus sales. Los comprimidos se preparan por compresión directa en condiciones de calor y de higrometría normales y con el equipamiento habitual para producir comprimidos.
ES98941377T 1997-07-23 1998-07-23 Composiciones farmaceuticas que contienen un par acido-base efervescente. Expired - Lifetime ES2191960T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97MI001746A IT1293764B1 (it) 1997-07-23 1997-07-23 Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua

Publications (1)

Publication Number Publication Date
ES2191960T3 true ES2191960T3 (es) 2003-09-16

Family

ID=11377613

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98941377T Expired - Lifetime ES2191960T3 (es) 1997-07-23 1998-07-23 Composiciones farmaceuticas que contienen un par acido-base efervescente.

Country Status (26)

Country Link
US (1) US6284272B1 (es)
EP (1) EP1003486B1 (es)
JP (1) JP4801255B2 (es)
KR (1) KR100528141B1 (es)
CN (1) CN1138535C (es)
AT (1) ATE232092T1 (es)
AU (1) AU743186B2 (es)
BG (1) BG64074B1 (es)
BR (1) BR9801335B1 (es)
CZ (1) CZ296221B6 (es)
DE (1) DE69811236T2 (es)
DK (1) DK1003486T3 (es)
EA (1) EA002608B1 (es)
ES (1) ES2191960T3 (es)
HU (1) HU226115B1 (es)
IL (1) IL134166A (es)
IT (1) IT1293764B1 (es)
NO (1) NO326639B1 (es)
NZ (1) NZ502479A (es)
OA (1) OA10999A (es)
PL (1) PL199164B1 (es)
PT (1) PT1003486E (es)
SI (1) SI1003486T1 (es)
SK (1) SK284551B6 (es)
TR (1) TR199900675T1 (es)
WO (1) WO1999004765A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040151768A1 (en) * 1997-07-23 2004-08-05 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
FR2786395A1 (fr) * 1998-12-01 2000-06-02 Virbac Sa Compositions seches solubles en presence d'eau et evitant la reaction de maillard a l'etat sec, leur preparation et leurs applications
CA2378525A1 (en) * 1999-07-02 2001-01-11 Sca Lohnherstellungs Ag A solid formulation of glucosamine sulphate
AP2002002410A0 (en) * 1999-08-04 2002-03-31 Ranbaxy Laboratories Ltd Hydrodynamically Balancing Oral Drug Delivery System
IN190018B (es) * 1999-09-28 2003-05-31 Panacea Biotec Ltd
GB0006897D0 (en) * 2000-03-23 2000-05-10 Smithkline Beecham Plc Medicaments
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
CA2419592A1 (en) * 2000-08-18 2002-02-28 Pharmacia Corporation Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
US6762153B2 (en) * 2001-10-18 2004-07-13 Rohm And Haas Company Delivery system for cyclopropenes
US20030091627A1 (en) * 2001-10-31 2003-05-15 Vinay Sharma Rate-controlled delivery of macrolides
KR100456273B1 (ko) 2001-11-16 2004-11-10 김용년 산과 반응하여 일정 속도로 이산화탄소를 발생시킬 수있는 고상 제제 및 그의 제조 방법
DK1490024T3 (da) 2002-03-06 2012-04-10 Effrx Pharmaceuticals Sa Alendronatholdige brusesammensætninger
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
BG730Y1 (bg) * 2003-03-20 2005-04-30 Владимир НАЙДЕНОВ Ефервесцентна лекарствена форма
CN100445263C (zh) * 2003-04-24 2008-12-24 四川大学 甘氨酸钠碳酸盐的微波合成方法
FR2876911B1 (fr) * 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant du piroxicam, une cyclodextrine et de l'arginine
EP2260871B1 (fr) 2004-04-01 2013-05-15 Pierre Fabre Medicament Complexes d'inclusions comprenant du piroxicam, une cyclodextrine et l'arginine
EP3216445A1 (en) * 2004-05-28 2017-09-13 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
CN100341488C (zh) * 2005-11-22 2007-10-10 瑞普（保定）生物药业有限公司 一种饮水免疫泡腾片及其制备方法
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008140772A2 (en) * 2007-05-08 2008-11-20 Hercules Incorporated Robust rapid disintegration tablet formulation
NZ602302A (en) 2007-12-28 2014-04-30 Impax Laboratories Inc Controlled release formulations of levodopa and uses thereof
US9629809B2 (en) 2008-07-21 2017-04-25 Si Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
EP2309988B1 (en) 2008-07-21 2015-11-25 SI Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
CA2792733C (en) * 2010-03-13 2015-06-02 Eastpond Laboratories Limited Fat-binding compositions comprising .alpha.- or .beta.-cyclodextrin
CN101836951B (zh) * 2010-05-20 2013-06-05 山东达因海洋生物制药股份有限公司 一种含盐酸氨溴索的口服溶液及其制备方法
CN102322123B (zh) * 2011-06-30 2013-09-18 德清艺玛工艺装饰有限公司 一种仿大理石泡沫装饰材料
CN102398378A (zh) * 2011-11-03 2012-04-04 北京华禧联合科技发展有限公司 镀铬冲模在硫酸氢氯吡格雷片制备过程中的应用
BR112015013945A8 (pt) * 2012-12-14 2019-10-08 Si Group Inc grânulos de alto teor de ibuprofeno de sódio, preparação do mesmo e uso do mesmo na preparação de formas de dosagem sólidas não-efervescentes
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP2870961B1 (en) * 2013-11-06 2018-07-18 Sanovel Ilac Sanayi ve Ticaret A.S. Effervescent formulations of pramipexole
US11844860B2 (en) 2018-03-02 2023-12-19 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196033B (it) * 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
DE3779500T2 (de) * 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
CH675537A5 (es) * 1988-03-25 1990-10-15 Ciba Geigy Ag
DE3838431A1 (de) * 1988-11-12 1990-05-17 Bayer Ag Ibuprofen-brausezubereitungen
ATE108649T1 (de) * 1990-02-14 1994-08-15 Takeda Chemical Industries Ltd Brausemischung, deren herstellung sowie verwendung.
US5252341A (en) * 1990-07-16 1993-10-12 Degussa Aktiengesellschaft Tablets and granulates containing mesna as active substance
JP2910425B2 (ja) * 1992-06-17 1999-06-23 和光純薬工業株式会社 発泡性錠剤の新規な製造方法
JP3170139B2 (ja) * 1994-04-08 2001-05-28 エスエス製薬株式会社 発泡性錠剤
FR2733420B1 (fr) * 1995-04-28 1997-06-27 Sep Tarral Preparations pectiques utilisables comme support de medicament
DE69726879T2 (de) * 1996-05-17 2004-10-14 Merck & Co., Inc. Biphosphonat-formulierung mit brausewirkung

Also Published As

Publication number Publication date
AU743186B2 (en) 2002-01-17
WO1999004765A2 (en) 1999-02-04
HUP0003897A3 (en) 2006-06-28
EP1003486B1 (en) 2003-02-05
EP1003486A2 (en) 2000-05-31
ATE232092T1 (de) 2003-02-15
BR9801335A (pt) 1999-05-04
HK1029525A1 (en) 2001-04-06
PT1003486E (pt) 2003-06-30
CN1138535C (zh) 2004-02-18
SK922000A3 (en) 2000-07-11
OA10999A (en) 2001-11-07
BR9801335B1 (pt) 2010-09-21
CZ296221B6 (cs) 2006-02-15
DE69811236T2 (de) 2003-10-30
DE69811236D1 (de) 2003-03-13
ITMI971746A1 (it) 1999-01-23
IL134166A0 (en) 2001-04-30
EA002608B1 (ru) 2002-06-27
KR20010022140A (ko) 2001-03-15
BG64074B1 (bg) 2003-12-31
KR100528141B1 (ko) 2005-11-15
BG103253A (en) 1999-09-30
NZ502479A (en) 2002-02-01
SI1003486T1 (en) 2003-08-31
JP2001510789A (ja) 2001-08-07
IL134166A (en) 2005-08-31
US6284272B1 (en) 2001-09-04
NO991376L (no) 1999-05-25
CN1267215A (zh) 2000-09-20
TR199900675T1 (xx) 1999-11-22
DK1003486T3 (da) 2003-05-19
HUP0003897A2 (hu) 2001-08-28
SK284551B6 (sk) 2005-06-02
NO326639B1 (no) 2009-01-26
JP4801255B2 (ja) 2011-10-26
EA200000062A1 (ru) 2000-10-30
AU8977798A (en) 1999-02-16
CZ2000255A3 (cs) 2000-07-12
NO991376D0 (no) 1999-03-22
PL199164B1 (pl) 2008-08-29
WO1999004765A3 (en) 1999-06-10
HU226115B1 (en) 2008-04-28
IT1293764B1 (it) 1999-03-10
PL338502A1 (en) 2000-11-06

Similar Documents

Publication Publication Date Title
NO991376L (no) Farmas°ytiske sammensetninger inneholdende et brusende syre-base par
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
DE69626117D1 (de) Orale pharmazeutische zusammensetzungen mit verzögerter freisetzung von reversiblen protonpumpen-inhibitoren
DOP2001000241A (es) Formulaciones de liberación sostenida para secretagogos de hormona del crecimiento
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
SV2004001418A (es) Formulaciones farmaceuticas de 5,7,14-triazaciclo 10.3.1.0.2,11.04,9) -hexadeca-2(11),3,5,7,9-pentaeno" ref.pc 23248
UY27320A1 (es) Nuevas composiciones farmacéuticas
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
CO5160272A1 (es) Combinacion de cerivastatina y fibratos
UY32624A (es) Procedimiento y composición para mejorar la absorción de agentes terapéuticos
CO5540295A2 (es) Comprimido para tragar que comprende paracetamol
ATE347358T1 (de) Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
DOP2002000373A (es) Composiciones que contienen imidazotriazinona para administración nasal
CO5650230A2 (es) Composiciones estables de atorvastatina preparadas con granulacion en humedo
EE05235B1 (et) Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine
PE20050368A1 (es) Jarabe multivitaminico para ninos o adultos jovenes
WO2003028624A3 (en) Levothyroxine compositions and methods
NO20044723L (no) Injiserbare veterinaermedisinske sammensetninger for sma dyr
ATE291421T1 (de) Pharmazeutische, ramipril enthaltende brauseformulierung
AR027287A1 (es) Gonadotrofina
WO2003013441A3 (en) Levothyroxine compositions and methods
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
MX2023005639A (es) Comprimidos de capa doble orales que comprenden acido acetilsalicilico y pseudoefedrina, metodos para preparar y utilizar los mismos.
AR043129A1 (es) Combinacion de farmacos antidiabeticos